| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/27/2005 | WO2005007644A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | WO2005007641A1 2-pyridine alkyne derivatives useful for treating pain |
| 01/27/2005 | WO2005007179A1 Composition containing ground lotus and/or lotus extract and lactic acid bacterium |
| 01/27/2005 | WO2005007155A1 Medicinal composition |
| 01/27/2005 | WO2003090687A3 Using heat shock proteins to increase immune response |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2003057826A3 SOLUBLE GLcNAC PHOSPHOTRANSFERASE |
| 01/27/2005 | US20050020677 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/27/2005 | US20050020670 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran |
| 01/27/2005 | US20050020661 Antidiabetic agents |
| 01/27/2005 | US20050020657 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |
| 01/27/2005 | US20050020652 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus |
| 01/27/2005 | US20050020647 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
| 01/27/2005 | US20050020642 Antiinflammatory agents; antiarthritic agents; anticancer agents; angiogenesis inhibitors; asthma therapy; cyclooxygenase inhibitor |
| 01/27/2005 | US20050020634 Acat inhibitors; cardiovascular disorders; restenosis; Alzheimer's disease |
| 01/27/2005 | US20050020624 Dihydroindole and tetrahydroquinoline derivatives |
| 01/27/2005 | US20050020621 Prevent reduced blood flow to brain |
| 01/27/2005 | US20050020617 3-substituted oxindole beta3 agonists |
| 01/27/2005 | US20050020614 Stabilization plaque in blood vessels; therapy for restenosis in diabetic patients |
| 01/27/2005 | US20050020609 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020602 Bone disorders; reduction concentration of parathyroid hormone in blood |
| 01/27/2005 | US20050020597 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease |
| 01/27/2005 | US20050020593 Anticancer agents |
| 01/27/2005 | US20050020584 Benzamide derivatives as antagonists of orexin receptors |
| 01/27/2005 | US20050020583 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/27/2005 | US20050020578 Oxidoreductase enzyme inhibitors such as (R)-1-[4-(2-methyl-4-phenyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-pyrimidin-2-yl-ethanol, used as antidiabetic agents |
| 01/27/2005 | US20050020573 5HT2c receptor modulators |
| 01/27/2005 | US20050020572 Therapy for bacteria infections |
| 01/27/2005 | US20050020571 Antiserotonine agents; psycholgical disorders; headaches |
| 01/27/2005 | US20050020570 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| 01/27/2005 | US20050020545 Substituted tetracycline compounds as antifungal agents |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020504 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 01/27/2005 | US20050020498 Apo-2 ligand/trail formulations |
| 01/27/2005 | US20050020496 Diagnosis, hormone replacement therapy for HIV positive females, gene therapy; metabolic disorders; antidiabetic, anticholesterol, hypoglycemic agents |
| 01/27/2005 | US20050020492 Melanin-concentrating hormone analogs |
| 01/27/2005 | US20050020480 Administering a steroid |
| 01/27/2005 | US20050019929 Deleted adenovirus vectors and methods of making and administering the same |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019921 Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019889 Human osteoclast derived cathepsin |
| 01/27/2005 | US20050019882 Using plant enzymes for the production of flavor, fragrance, pharmaceutical or bio-control agents from less valuable substrates; terpenoid biosynthesis |
| 01/27/2005 | US20050019866 Nucleotide sequences coding membrane protein for use in diagnosis, detection, prevention and/or treatment of cell proliferative disorders |
| 01/27/2005 | US20050019858 Novel human cytokine/steroid receptor protein |
| 01/27/2005 | US20050019835 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/27/2005 | US20050019821 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/27/2005 | US20050019763 Isolated polypeptide of given sequence; expression vectors, host cells, antibodies, agonists, and antagonists; use in diagnosing, treating, or preventing various disorders |
| 01/27/2005 | US20050019433 Negatively charged polysaccharide derivable from aloe vera |
| 01/27/2005 | US20050019426 Use of an aqueous or hydroalcoholic extract from bauhinia for the preparation of a composition |
| 01/27/2005 | US20050019334 Interleukin antibody or fusion protein; comprising active material and FC domain; Escherichia coli cells |
| 01/27/2005 | US20050019324 Peptides and antibodies to muc 1 proteins |
| 01/27/2005 | US20050019313 Genetic engineering; supplying stem cells; genes code cytosine deaminase; central nervous system tumors |
| 01/27/2005 | US20050019271 Glycopyrrolate in sustained releae form; antimuscarinic agents |
| 01/27/2005 | CA2532806A1 Medicinal composition |
| 01/27/2005 | CA2529790A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| 01/27/2005 | CA2525949A1 Transgenic cells expressing proteins involved in fatty acid biosynthesis |
| 01/26/2005 | EP1500707A1 Method of measuring neprilysin activity |
| 01/26/2005 | EP1500702A1 APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| 01/26/2005 | EP1500658A1 Novel thiol derivative, process for producing the same and use thereof |
| 01/26/2005 | EP1500657A1 Substituted pyrazoles as P38 kinase inhibitors |
| 01/26/2005 | EP1500656A1 Biguanide derivative and therapeutic agent for diabetes containing the same |
| 01/26/2005 | EP1500654A1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 01/26/2005 | EP1500648A1 Novel piperidine derivative |
| 01/26/2005 | EP1500643A1 Benzamide derivatives |
| 01/26/2005 | EP1500403A1 Preventive/remedy for diabetes |
| 01/26/2005 | EP1500402A1 Cell death inhibitor |
| 01/26/2005 | EP1500401A1 Drugs for treating vascular diseases |
| 01/26/2005 | EP1500400A1 Drug containing antibody composition |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499742A1 Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes |
| 01/26/2005 | EP1499736A1 Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499622A1 Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors |
| 01/26/2005 | EP1499621A1 Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors |
| 01/26/2005 | EP1499619A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and method for the production thereof |
| 01/26/2005 | EP1499618A1 Furyl compounds |
| 01/26/2005 | EP1499616A1 Heterocyclic compounds |
| 01/26/2005 | EP1499615A1 Thienyl compounds |
| 01/26/2005 | EP1499611A1 Process for 5- 2(r)- 1(r)- 3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one |
| 01/26/2005 | EP1499608A1 Substituted imidazole derivatives: gaba a receptor ligands |
| 01/26/2005 | EP1499605A2 NF-KappaB INHIBITORS |
| 01/26/2005 | EP1499601A1 New 2-substituted -1,3-thiazole compounds |
| 01/26/2005 | EP1499600A1 Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors |
| 01/26/2005 | EP1499599A1 Substituted pyrazine derivatives |
| 01/26/2005 | EP1499597A2 Compounds and methods for inducing apoptosis in proliferating cells |
| 01/26/2005 | EP1499594A1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles |
| 01/26/2005 | EP1499593A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
| 01/26/2005 | EP1499589A1 Derivatives of n-phenyl(piperidin-2-yl)methyl benzamide, the preparation method thereof and application of same in therapeutics |
| 01/26/2005 | EP1499585A1 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 01/26/2005 | EP1499578A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 01/26/2005 | EP1499577A1 2-(2,6-dichlorophenyl)-diarylimidazoles |
| 01/26/2005 | EP1499360A2 Formulation comprising buprenorphine |
| 01/26/2005 | EP1499352A1 Recombinant anti-interleukin-9 antibodies |
| 01/26/2005 | EP1499343A1 A method of modulating cellular activity |